🇺🇸 FDA
Patent

US 8173123

Methods of treating colitis involving IL-13 and NK-T cells

granted A61KA61K2039/505A61P

Quick answer

US patent 8173123 (Methods of treating colitis involving IL-13 and NK-T cells) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/505, A61P, A61P1/00, A61P1/04